| Not Yet Recruiting | A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer NCT07225309 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce NCT07459673 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management NCT07371585 | SOLTI Breast Cancer Research Group | Phase 2 |
| Recruiting | HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC NCT06830382 | Renske Altena | — |
| Enrolling By Invitation | Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DX NCT06680596 | UNICANCER | Phase 2 |
| Active Not Recruiting | Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negat NCT06889688 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 |
| Recruiting | A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer NCT06678269 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Not Yet Recruiting | A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer NCT04469127 | Advanced Imaging Projects, LLC | Phase 1 / Phase 2 |
| Not Yet Recruiting | Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Brea NCT06578299 | Fudan University | Phase 4 |
| Recruiting | Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy NCT06268665 | University of California, Davis | Phase 2 |
| Recruiting | HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan NCT06236269 | SOLTI Breast Cancer Research Group | Phase 2 |
| Recruiting | RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study NCT07030569 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Recruiting | A Study of Pembrolizumab and Cryoablation in People With Breast Cancer NCT06246968 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study NCT06234488 | Medical College of Wisconsin | — |
| Recruiting | A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer NCT06075810 | MBQ Pharma | Phase 1 |
| Active Not Recruiting | Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) NCT05625087 | UNICANCER | Phase 2 |
| Not Yet Recruiting | Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis NCT05860907 | Fudan University | Phase 4 |
| Recruiting | A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. NCT06064812 | Forward Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain NCT05866432 | Medical University of Vienna | Phase 2 |
| Completed | Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients NCT05837533 | Medicos e Investigadores en la Lucha contra el Cancer de Mama | N/A |
| Recruiting | Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advan NCT06805812 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Unknown | RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody NCT06481553 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | — |
| Unknown | Study of Dotatate Imaging in Breast Cancer NCT05880394 | Hoag Memorial Hospital Presbyterian | Phase 2 |
| Recruiting | Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer NCT05377047 | Vastra Gotaland Region | N/A |
| Unknown | Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patient NCT05670054 | Mansoura University | Phase 3 |
| Completed | A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer NCT05190770 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Withdrawn | Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Ca NCT04896320 | Providence Health & Services | Phase 1 / Phase 2 |
| Unknown | Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients NCT05033925 | Gadjah Mada University | Phase 1 / Phase 2 |
| Active Not Recruiting | Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer NCT05090358 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Sitravatinib in Metastatic Breast Cancer NCT04123704 | Xiang Zhang | Phase 2 |
| Completed | A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer NCT05054374 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Unknown | BRaziLian outcomE for metAStatic breasT Cancer NCT05559528 | Hospital do Coracao | — |
| Active Not Recruiting | Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxici NCT05036252 | Memorial Sloan Kettering Cancer Center | — |
| Unknown | Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells NCT04628806 | Charite University, Berlin, Germany | — |
| Recruiting | SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells NCT04150042 | General Oncology, Inc. | Phase 1 |
| Unknown | Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observationa NCT04852081 | Blokhin's Russian Cancer Research Center | — |
| Unknown | The Benefit of Surgery in Stage IV of Breast Cancer NCT04697043 | Tehran University of Medical Sciences | N/A |
| Completed | RWD Study in HER2+ mBC Patients in Third-Line Therapy NCT04566458 | Exactis Innovation | — |
| Completed | Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases NCT04752059 | Medical University of Vienna | Phase 2 |
| Active Not Recruiting | Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer NCT03324425 | Baylor Breast Care Center | Phase 2 |
| Active Not Recruiting | Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients NCT03870919 | UNICANCER | N/A |
| Completed | Clinical Outcome and Toxicity Data in Patients With Advanced Breast Cancer Treated With CDK Inhibitors Combine NCT04133207 | Hellenic Cooperative Oncology Group | — |
| Completed | Self-Advocacy Serious Game in Advanced Cancer NCT03339765 | University of Pittsburgh | N/A |
| Completed | A Whole-food, Plant-Based Nutrition Intervention in Women With Metastatic Breast Cancer NCT03045289 | University of Rochester | N/A |
| Unknown | The Resistance and Immune Response to Palbociclib in Breast Cancer NCT03401359 | Samsung Medical Center | N/A |
| Withdrawn | Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients NCT03032614 | The University of Texas Health Science Center at San Antonio | Phase 2 |
| Completed | PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer NCT03304210 | University Hospital, Ghent | Phase 1 |
| Completed | To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumo NCT03159585 | Zhujiang Hospital | Phase 1 |
| Terminated | Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Brea NCT03202446 | Eske Corporation S.A.C | Phase 3 |
| Completed | A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer NCT02448771 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Completed | Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer NCT00393341 | Indiana University School of Medicine | — |